Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 27 October 2014 | By Alexander Gaffney, RAC,
Most Warning Letters sent by the US Food and Drug Administration (FDA) are met by their recipients with a sense of loathing and urgency. A failure to respond to a letter quickly and appropriately can lead to major sanctions against a company, to say nothing of the damage a bungled response can do to a company's reputation.
But one company, cited by FDA in September 2014 Warning Letter alleging that it improperly marketed a product to treat Ebola, is fighting back in an unusual manner: through FDA's Citizen Petition Process.
Warning Letters are used by FDA to warn companies that regulators consider their actions to be contrary to either regulations or the law, and that a failure to take corrective actions may lead to more serious enforcement actions or penalties. The letters generally follow an inspection of a company's physical manufacturing operations by FDA employees, but may also follow an inspection of a company's website.
Citizen Petitions, on the other hand, are the public's way of warning FDA—of policies that are outdated, products that should be approved, decisions which should be overturned or a need for additional information. Though the petitions are often used in industry, they are rarely—if ever—used to comment on specific Warning Letters.
But following the release of several Warning Letters in September 2014 to companies allegedly marketing their products as being able to treat the Ebola virus, one company is using the Citizen Petition process to fight back.
In a petition to FDA, Natural Solutions Foundation, a New Jersey-based marketer of dietary products cited in one of the September 2014 Warning Letters, asks the agency to allow it to market its products using FDA's "enforcement discretion" authority. That authority is occasionally used by FDA to allow products which would otherwise not meet federal regulations to remain on the market, such as during a drug shortage or in other public health emergencies.
The agency should use its discretion to allow the "free and open discussion" of the potential utility of the company's Nano Silver product to treat or prevent Ebola, the company said.
FDA's letter said the company's claims that Nano Silver could be used to treat, prevent or inhibit the Ebola virus were a clear violation of the Federal Food, Drug and Cosmetic Act (FD&C Act), which bans the use of such claims for products which are not explicitly approved for that purpose by FDA.
The company has become something of a punching bag for FDA, whose leader, Commissioner Margaret Hamburg has taken to referencing the company's marijuana constituent-infused chocolate bar—also promoted as an Ebola treatment—as a clear sign of quackery. "Note to audience: Do not buy," she told a conference of health industry professionals in October 2014.
Natural Solutions Foundation's petition also contains a copy of its response to FDA's Warning Letter in which it pledges to stop selling the two products referenced in FDA's Warning Letter and alter the marketing of its products. At the time of this article's publication, the company's website still contains numerous references to Ebola.
Tags: Citizen Petition, Warning Letter, Ebola
Regulatory Focus newsletters
All the biggest regulatory news and happenings.